Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
FATE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $5.92
Previous CloseN/A
Volume630.90K
Average Volume (3M)1.96M
Market Cap
$143.25M
Enterprise Value$560.80K
Total Cash (Recent Filing)$4.65M
Total Debt (Recent Filing)$3.19M
Price to Earnings (P/E)―
Beta2.95
Next Earnings
Apr 30, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding114,603,910
10 Day Avg. Volume2,440,121
30 Day Avg. Volume1,958,798
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.68
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.17Price Target Upside350.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Clinical ResultsA case study for the first SLE patient treated with 360M cells of FT819 demonstrated disease remission at 6+ months, low disease activity, and resolution of key quality of life metrics.
Regulatory SupportThe FDA agreed to allow the investigation of additional autoimmune diseases in the current Phase 1 study, indicating regulatory support.
Safety And DifferentiationSafety was commendable, and the flu-free conditioning is an attractive point of differentiation.
Bears Say
Conflict Of InterestThere is a potential conflict of interest as Wedbush Securities may have a conflict of interest that could affect the objectivity of this report.
Financial PerformanceThe net loss per share was reported to be slightly higher than the consensus estimate.
Investor SentimentPoor durability of response in the early systemic lupus erythematosus cohorts may be disappointing to investors.
---
Ownership Overview
18.11% Insiders
15.79% Mutual Funds
0.30% Other Institutional Investors
55.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $0.66 and its highest was $5.92 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is $143.25M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Apr 30, 2025 which is in 7 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Mar 05, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.432 by -$0.008.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 114,603,910 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.432. Following the earnings report the stock price went up 15.556%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in FATE
---
Fate Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.17 (350.36% Upside)
$6.17 (350.36% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $31.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.90%
12-Months-Change
Fundamentals
Return on Equity
-54.21%
Trailing 12-Months
Asset Growth
-12.94%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
---
FATE Stock 12 Month Forecast
Average Price Target
$6.17
▲(350.36% Upside)
Technical Analysis
Korro Bio
―
ADC Therapeutics
―
Silence Therapeutics
―
Seer
―
4D Molecular Therapeutics
―
Best Analysts Covering FATE
1 Year
1 Year Success Rate
4/17 ratings generated profit
1 Year Average Return
-23.38%
reiterated a buy rating 2 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -23.38% per trade.
---